Evaluating Sublingual immunotherapy in allergic Rhinoconjunctivitis
Phase 4
- Conditions
- Ear, Nose and ThroatEye Diseases
- Registration Number
- PACTR201901529431463
- Lead Sponsor
- Faculty of Medicine Zagazig University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Adolescent or adult Patient with a history of moderate to severe chronic allergic rhinoconjunctivitis without any co-morbidities.
Exclusion Criteria
The study excluded any patient with active, acute, or chronic obstructive pulmonary disease, except for asthma and allergic rhinitis; forced expiratory volume in 1 s = 70% of predicted value;
Patients who have disorders concerning drug absorption, distribution, metabolism, and excretion.
Inability to perform Skin prick test in patients included in group 2.
Illiterate patients who cannot read the self-administered quality of life questioner were also excluded.
Refusal of consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of patients Quality of life
- Secondary Outcome Measures
Name Time Method Improvement in patient Medication score